Abstract
Neuroblastoma (NB) is a malignant pediatric tumor originating from undifferentiated neural crest cells. About 20 % of high-risk group patients are high-risk group patients are refractory to first line therapy and about 50 % of initial responders later develop a relapse. There is no common tactics for salvage therapy. In spite of a c relatively high response rate observed for most second- and third-line therapy regimens used, the long-term event-free survival is still as low as 5 %, which implies a need for consolidation, e.g. by allogeneic hematopoietic stem cell transplantation (allo-HSCT) from haploidentical donor. We present a case report of a patient with systemic NB relapse achieving a long-term disease stabilization after a haplo-HSCT and post-transplant therapy.
Highlights
Long-term disease stabilization in a patient with relapsed neuroblastoma after allogeneic hematopoietic stem cell transplantation
Neuroblastoma (NB) is a malignant pediatric tumor originating from undifferentiated neural crest cells
In spite of a c relatively high response rate observed for most second- and third-line therapy regimens used, the long-term event-free survival is still as low as 5 %, which implies a need for consolidation, e.g. by allogeneic hematopoietic stem cell transplantation from haploidentical donor
Summary
Long-term disease stabilization in a patient with relapsed neuroblastoma after allogeneic hematopoietic stem cell transplantation. Одним из методов консолидации может быть аллогенная трансплантация гемопоэтических стволовых клеток (алло-ТГСК) от гаплоидентичного донора. В статье представлен клинический случай пациента с системным рецидивом НБ, у которого удалось достичь длительного ответа после алло-ТГСК от гаплоидентичного донора и посттрансплантационной иммуноадоптивной терапии.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Russian Journal of Children Hematology and Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.